Literature DB >> 11532390

Control of muscle development by dueling HATs and HDACs.

T A McKinsey1, C L Zhang, E N Olson.   

Abstract

Skeletal muscle cells have provided an especially auspicious system in which to dissect the roles of chromatin structure in the control of cell growth, differentiation, and development. The MyoD and MEF2 families of transcription factors act cooperatively to regulate the expression of skeletal muscle-specific genes. Recent studies have shown that these two classes of transcription factors associate with histone acetyltransferases and histone deacetylases to control the activation and repression, respectively, of the muscle differentiation program. Signaling systems that regulate the growth and differentiation of muscle cells act, at least in part, by regulating the intracellular localization and associations of these chromatin remodeling enzymes with myogenic transcription factors. We describe the molecules and mechanisms involved in chromatin remodeling during skeletal muscle development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532390     DOI: 10.1016/s0959-437x(00)00224-0

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  151 in total

1.  MicroRNA-214 promotes myogenic differentiation by facilitating exit from mitosis via down-regulation of proto-oncogene N-ras.

Authors:  Jun Liu; Xiao-Ju Luo; An-Wen Xiong; Zeng-di Zhang; Shen Yue; Ming-Sheng Zhu; Steven Y Cheng
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

2.  Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6 expression and activity in skeletal muscle.

Authors:  Nima Alamdari; Ira J Smith; Zaira Aversa; Per-Olof Hasselgren
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-06-10       Impact factor: 3.619

Review 3.  Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.

Authors:  Dan P Christensen; Mattias Dahllöf; Morten Lundh; Daniel N Rasmussen; Mette D Nielsen; Nils Billestrup; Lars G Grunnet; Thomas Mandrup-Poulsen
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

Review 4.  Regulating histone acetyltransferases and deacetylases.

Authors:  Gaëlle Legube; Didier Trouche
Journal:  EMBO Rep       Date:  2003-10       Impact factor: 8.807

5.  Cyclin D-cdk4 activity modulates the subnuclear localization and interaction of MEF2 with SRC-family coactivators during skeletal muscle differentiation.

Authors:  Jean-Bernard Lazaro; Peter J Bailey; Andrew B Lassar
Journal:  Genes Dev       Date:  2002-07-15       Impact factor: 11.361

6.  Expression of a mutant lamin A that causes Emery-Dreifuss muscular dystrophy inhibits in vitro differentiation of C2C12 myoblasts.

Authors:  Catherine Favreau; Dominique Higuet; Jean-Claude Courvalin; Brigitte Buendia
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

7.  Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle.

Authors:  Eric J Stevenson; Paul G Giresi; Alan Koncarevic; Susan C Kandarian
Journal:  J Physiol       Date:  2003-07-04       Impact factor: 5.182

8.  Transcription factor interactions and chromatin modifications associated with p53-mediated, developmental repression of the alpha-fetoprotein gene.

Authors:  Thi T Nguyen; Kyucheol Cho; Sabrina A Stratton; Michelle Craig Barton
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

9.  mef2ca is required in cranial neural crest to effect Endothelin1 signaling in zebrafish.

Authors:  Craig T Miller; Mary E Swartz; Patricia A Khuu; Macie B Walker; Johann K Eberhart; Charles B Kimmel
Journal:  Dev Biol       Date:  2007-05-24       Impact factor: 3.582

10.  Differential role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream of MyoD and Myf5.

Authors:  Jeanne-Françoise Roth; Noriko Shikama; Clea Henzen; Isabelle Desbaillets; Werner Lutz; Silvia Marino; Jonas Wittwer; Hubert Schorle; Max Gassmann; Richard Eckner
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.